The aim of current study was to develop and validate a rapid, explicit and vigorous assay based on solid phase extraction and liquid chromatographyelectrospray ionization tandem mass spectrometry (LC-ESI MS-MS) for the simultaneous quantitative analysis of Irbesartan and Hydrochlorothiazide in human plasma using Losartan and Hydroflumethiazide as internal standards (IS). The precursor to product ion transitions of m/z 427.3/ 193.0 and m/z 295.8/ 205.1 were used to measure the Irbesartan and Hydrochlorothiazide respectively. The method was validated over a concentration range of 99.9 to 6274.0 ng mL-1 for Irbesartan and 3.18 to 500.45 ng mL-1 for Hydrochlorothiazide. The method was validated over the parameters like selectivity, matrix effect, sensitivity, linearity, precision and accuracy various stabilities (bench top stability, standard stock solution stability, stock dilution stability, auto sampler stability, freeze thaw stability, long term stability), effect of potentially interfering drugs, dilution integrity, recovery and reinjection reproducibility. The mean % recovery of Irbesartan, Hydrochlorothiazide, Losartan and Hydroflumethiazide were 89.03 %, 83.15 %, 88.89 % and 84.89 % with a precision of 9.39 %, 2.79 %, 4.36 % and 2.12 % respectively. The RSD % of intra-day and inter-day assay was ≤15%. The application of this assay was demonstrated in a bioequivalence study after an oral administration of a tablet containing higher dose of Hydrochlorothiazide and Irbesartan in healthy volunteers.